ESPL1: Regulating Cell Death and Growth (G9700)

Target Name: ESPL1

NCBI ID: G9700

ESPL1

ESPL1: Regulating Cell Death and Growth

ESPL1 (caspase-like protein ESPL1) is a protein that is expressed in various cell types, including neurons, neurons progeny, and glial cells. Its primary function is to regulate cell death, which is a critical process that regulates the development and maintenance of tissues. ESPL1 plays a crucial role in cell apoptosis, which is the process by which cells undergo programmed cell death.

ESPL1 is a member of the Bcl-2 family, which is a well-known family of proteins that are involved in cell death. The Bcl-2 family includes several proteins, including Bcl-2, Bcl-3, Bcl-4, and Bcl-5. These proteins are involved in various cellular processes, including cell apoptosis, cell growth, and cell survival.

One of the key functions of ESPL1 is its role in cell apoptosis. When a cell is facing the possibility of death, ESPL1 helps to coordinate the process of cell death. This is done by activating various signaling pathways that ultimately result in the release of pro-inflammatory cytokines, which can cause tissue damage and contribute to the development of diseases.

In addition to its role in cell apoptosis, ESPL1 is also involved in the regulation of cell growth. It has been shown to play a negative role in the growth of cancer cells, which is thought to contribute to the development of cancer. This is done by inhibiting the ability of ESPL1 to promote cell growth and the production of cell cycle proteins.

ESPL1 has also been shown to be involved in the regulation of cellular processes that are important for brain development and function. This is done by interacting with specific proteins that are involved in the development and maintenance of neural stem cells, as well as the regulation of neurotransmitter release.

Due to its involvement in these critical cellular processes, ESPL1 has potential as a drug target or biomarker. For example, drugs that target ESPL1 have been shown to be effective in treating various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression.

In addition to its potential therapeutic applications, ESPL1 is also a useful biomarker for certain diseases. For example, ESPL1 has been shown to be decreased in the brains of individuals with Alzheimer's disease, which is thought to be due to the loss of ESPL1-positive neurons. This suggests that ESPL1 may be a useful biomarker for the diagnosis and progression of Alzheimer's disease.

Overall, ESPL1 is a protein that is involved in various cellular processes that are important for cell survival and development. Its functions include regulating cell death, cell growth, and neural stem cell development. As a result, ESPL1 has potential as a drug target or biomarker for the treatment of various neurological and psychiatric disorders. Further research is needed to fully understand the role of ESPL1 in these processes and to develop effective treatments.

Protein Name: Extra Spindle Pole Bodies Like 1, Separase

Functions: Caspase-like protease, which plays a central role in the chromosome segregation by cleaving the SCC1/RAD21 subunit of the cohesin complex at the onset of anaphase. During most of the cell cycle, it is inactivated by different mechanisms

The "ESPL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ESPL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets